Bionano Genomics Inc. priced an underwritten offering of common shares and warrants to purchase common shares to raise about $18 million in gross proceeds.
The San Diego-based company is selling 20,937,558 common shares or prefunded warrants to purchase common shares, along with warrants to purchase the same number of common shares in the offering.
Each common share or prefunded warrant is being sold at 86 cents along with an accompanying warrant. For each prefunded warrant sold, the number of shares being offered by the company will decrease by one.
The common warrants will be immediately exercisable at the same price and will expire five years from the date of issuance.
Each warrant issued in the offering can be exercised for 86 cents to purchase a common share of Bionano for up to five years.
Bionano expects to close the offering on Oct. 23, subject to customary conditions.
The company plans to use proceeds for general corporate purposes, including working capital, sales and marketing activities. Funds raised will also support general and administrative matters and capital expenditures.
Oppenheimer & Co. Inc. is the sole book-running manager for the offering. Roth Capital Partners and Maxim Group LLC are lead and co-lead managers, respectively.